Estradiol hexahydrobenzoate/hydroxyprogesterone caproate/testosterone hexahydrobenzoate

(Redirected from Trinestril AP)

Estradiol hexahydrobenzoate/hydroxyprogesterone caproate/testosterone hexahydrobenzoate (EHHB/OHPC/THHB), sold under the brand name Trinestril AP, is an injectable combination medication of estradiol hexahydrobenzoate (EHHB), an estrogen, hydroxyprogesterone caproate (OHPC), a progestogen, and testosterone hexahydrobenzoate (THHB), an androgen/anabolic steroid.[1] It contained 3 mg EHHB, 75 mg OHPC, and 100 mg THHB and was administered by intramuscular injection once per month.[1] The medication was marketed by 1957.[2]

EHHB/OHPC/THHB
Combination of
Estradiol hexahydrobenzoateEstrogen
Hydroxyprogesterone caproateProgestogen
Testosterone hexahydrobenzoateAndrogen; Anabolic steroid
Clinical data
Trade namesTrinestril AP
Other namesEHHB/OHPC/THHB
Routes of
administration
Intramuscular injection

See also

edit

References

edit
  1. ^ a b Revista de ginecologia e d'obstetricia ... January 1966. p. 55. UMA ÚNICA INJEÇlO POR MÊS TRINESTRYL A.P. Em todos os períodos da MENOPA USA Hemorragias uterinas funcionais • Fibromas Desnutrição • Osteoporose • Distúrbios neuropsíquicos da mulher idosa • hexahidrobenzoato de estradiol... 3 mg • enanto de 17 alfa-hidroxiprogesterono... 75 mg... • hexahidbrobenzoato de testosterona... 100 mg.
  2. ^ de Freitas P (October 2011). "O processo de medicalização da menopausa através dos conteúdos dos anúncios de medicamento". Métis: História & Cultura. 9 (18). Archived from the original on 2018-05-02. Retrieved 2019-06-24.